5 Blossom Street,

Boston,

MA,

US,

ZIP: 02114

Phone: +1 617 455 4188

With a tight lens on late translational through to phase II clinical progress; the 2nd Chronic HBV Drug Development Summit is dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms.

This industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts. From dissecting safe induction of innate and adaptive immune pathways and elucidating the role of T-cells in clearing virus infections, to clinical progress in combination therapy and assessing durability of surface antigen seroclearance, don’t miss your chance to join the conversation.

Harness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences, Vir Biotechnology, VBI Vaccines, Altimmune, Drug Farm, Replicor and many more to guide your strategic decisions and drive clinical progress to achieve functional cure for chronic HBV.

Tickets    https://go.evvnt.com/966899-2?pid=1052
Brochure https://go.evvnt.com/966899-3?pid=1052

Prices:
Conference + Workshop Day - Drug Developer USD 3946.00
Conference Only - Drug Developer USD 2599.00
Conference + Workshop Day - Academic USD 3096.00
Conference Only - Academic USD 2199.00
Conference + Workshop Day - Service Provider USD 4846.00
Conference Only - Service Provider USD 3099.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Development

Alexander Ploss Associate Professor of Molecular Biology Princeton University, Andrew Vaillant Chief Scientific Officer Replicor, Bertrand Georges Chief Technology Officer Altimmune, Carey Hwang Senior Vice President, Clinical Research, Head of Chronic Infection Vir Biotechnology, Chari Cohen Senior Vice President Hepatitis B Foundation, David Anderson Chief Scientific Officer VBI Vaccines, Francisco Diaz- Mitoma Chief Medical Officer VBI Vaccines, Helmut Brunar Chief Executive Officer Viravaxx, Herbert Virgin Chief Scientific Officer & Executive Vice President of Research Vir Biotechnology, Hubert Trübel Chief Medical Officer AiCuris, Jeysen Yogaratnam Chief Medical Officer Drug Farm, Katie Kitrinos Vice President, Clinical Virology Assembly Biosciences, Kees Melief Chief Scientific Officer ISA Pharmaceuticals, Linong Zhang Director Sanofi Pasteur, Luisa Stamm Chief Medical Officer Assembly Biosciences, Mark Dybul Chief Executive Officer Enochian BioSciences, Martin Leivers Senior Director, Early Development Leader GSK, Michael Newman Founder & Chief Scientific Officer Indaptus Therapeutics, Nezam Afdhal Chief of the Division of Gastroenterology, Hepatology & Nutrition Beth Israel Deaconess Medical Center, Patricia Mendez Head HBV Cure Gilead Sciences, Patrick Kennedy Clinical Professor of Translational Hepatology Queen Mary University Of London, Rajan George Founder, President & Chief Executive Officer Akshaya Bio, Shihyun You Senior Scientific Director GSK, Thomas Baumert Professor of Medicine, Head Inserm Research Institute, Chair Hepatology University Hospital, Timothy Block President Hepatitis B Foundation